Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Gynecologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Alpelisib × 1 year × Clear all
NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Novartis

Phase 3 Terminated
358 enrolled 19 charts
Gynecologic

Ovarian Neoplasms

NCT04251533 2026-05-11

EPIK-B3

Novartis

Phase 3 Terminated
137 enrolled 21 charts
Breast

Triple Negative Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Stanford University

Phase 2 Completed
19 enrolled 10 charts
Breast

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

Novartis

Phase 2 Completed
383 enrolled 16 charts
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT03284957 2025-11-24

AMEERA-1

Sanofi

Phase 1/2 Terminated
136 enrolled 60 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡